Research programme: anti-HIV antibody - Biolex
Alternative Names: Anti-HIV antibody research programme - Biolex; sCD4-17bLatest Information Update: 16 Jul 2007
At a glance
- Originator Biolex
- Developer Biolex; Dow Chemical
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jul 2007 Discontinued - Preclinical for HIV infections prevention in USA (Topical)
- 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
- 25 Oct 2002 Epicyte has been awarded a NIH grant for the large-scale production of hybrid antibodies to block the tranasmission of HIV